Written question asked by Baroness Masham of Ilton (Crossbench) on Monday, 6 June 2022, in the House of Lords. It was due for an answer on Monday, 20 June 2022. It was answered by Lord Kamall (Conservative) on Tuesday, 14 June 2022 on behalf of the Department of Health and Social Care.
Non-tuberculous Mycobacteria: Screening
- Question
-
To ask Her Majesty's Government what measures are in place to test patients treated with macrolide therapy for non-tuberculous mycobacteria; and how many of these tests have been undertaken in England.
- Answer
-
No formal assessment has been made. Patients with non-tuberculous mycobacteria will continue to be managed in primary and secondary care settings and treated with the current available treatments known as ‘Guideline Based Therapy’ as recommended by the British Thoracic Society.
The British Thoracic Society guideline for the use of longterm macrolides in adults with respiratory disease suggests that patients who are able to expectorate should be considered for testing for non-tuberculous mycobacteria prior to starting long-term macrolide therapy. A copy of the guideline is attached. NHS England and NHS Improvement do not hold data on the number of tests undertaken.
Secondary information
- Type
- Written question
- Reference
- HL647
- Session
- 2022-23
- Attachment
- Guideline for Long Term Macrolide Use
- Grouped for answer
- Yes
- Subjects
- Medical treatments Screening Non-tuberculous mycobacteria
- Contains statistics
- Yes
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-06-14 14:52:48 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL647
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL647
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL647